Abstract
Among all related biomarkers, plasma phosphorylated tau (p-tau181) has demonstrated strong diagnostic performance in the very early stages of Alzheimer’s disease (AD), showing significant differences between AD patients and healthy controls. The aim of our present systematic review and meta-analysis was to roundly evaluate the clinical diagnostic value of plasma p-tau181 based on the Simoa platform in Chinese populations. We systematically searched five databases (Embase, PubMed, Cochrane Library, MEDLINE, and Web of Science) from inception to May 11th, 2024, as well as the references of retrieved relevant articles. We included prospective cohort studies and retrospective case-control studies in our analysis. Out of 1165 identified articles, 10 met the inclusion criteria for meta-analysis. Our quantitative analysis showed that plasma p-tau181 levels were significantly increased in patients with AD and mild cognitive impairment (MCI) compared to healthy controls (standard mean difference [SMD]: 1.45 [1.25 – 1.65], p<0.00001; SMD: 0.55 [0.31 – 0.78], p<0.00001) and were lower in MCI patients compared to AD patients (SMD: -0.88 [-0.93 – -0.82], p<0.00001). The reference values for plasma p-tau181 were 4.48 [95% confidence interval (CI): 4.01 – 5.00] for AD patients, 2.86 [95% CI: 2.45 – 3.34] for MCI patients, and 2.09 [95% CI: 1.90 – 2.30] for healthy controls. The meta-analysis confirmed that plasma p-tau181 significantly increases from healthy controls to mild cognitive impairment (MCI) and then to AD in the Chinese population. We also provide reliable reference values for plasma p-tau181, which contribute to the early diagnosis of AD in Chinese clinical settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Tianjin Science and Technology Leading Cultivation Enterprise Project (22YDPYSY0020)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://github.com/KeqiangYan/meta-analysis
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at